Company intelligence / Profile preview

SpliceBio

Barcelona, Catalonia, Spainsplice.bio ↗

Ownership: Private
Development stage: Other

Overview

SpliceBio has initiated a Phase 1/2 clinical trial for its lead candidate SB‑007, a dual-AAV gene therapy targeting Stargardt disease. The company’s proprietary protein splicing platform enables delivery of large genes that exceed the packaging capacity of standard AAV vectors. This approach addresses key limitations in current gene therapy technologies and has shown preclinical validation across multiple organs beyond the retina. The company aims to expand its pipeline into other currently untreatable genetic diseases[1][2][5].

Therapeutic areas: Ophthalmology
Modalities: Gene therapy (AAV-based)Protein splicing
Industry: Biotech

Drug pipeline

5 assets

SB-008

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Spark Therapeutics – collaboration on treatments for inherited retinal diseases[5].

Beyond the preview

Go deeper on SpliceBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpliceBio.

Explore the full profile